Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting

Main Article Content

Cory Rubin
Michigan Dermatology Institute, Waterford, Michigan, United States

Abel Jarell
allCUTIS Research, Inc., Portsmouth, New Hampshire, United States

Pierre-Andre Becherel
Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France

Elena Pezzolo
Department of Dermatology, San Bortolo Hospital, Vicenza, Italy

Fatima Albreiki
Tawam Hospital, Al Ain, United Arab Emirates

Tien Nguyen
First OC Dermatology, California, United States

Teodora Festini
LEO Pharma A/S, Ballerup, Denmark

Frank Vinther
LEO Pharma A/S, Ballerup, Denmark

Ida Vittrup
LEO Pharma A/S, Ballerup, Denmark

Diamant Thaçi
Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

Keywords

adverse event, atopic dermatiits, tralokinumab, Real-world

Abstract

N/A

References

1. Feldman SR, et al. J Dermatolog Treat. 2024;35(1):2345739

2. Ameen M, et al. Acta Derm Venereol. 2024;104:adv24339

3. Bieber T. Allergy. 2020;75(1):54-62

4.Wollenberg A, Blauvelt A, Guttan-Yassky E, et al. Br J Dermatol. 2021;184(3):437-449

5. Simpson EL, Blauvelt A, Silverberg JI, et al. Am J Clin Dermatol. 2024;25:139-148.

Article Sidebar

PDF
Published
2026-03-10
DOI: https://doi.org/10.25251/7mx6d484

Article Details

How to Cite
1.
Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. J of Skin. 2026;10(2):s730. doi:10.25251/7mx6d484
Issue
Vol. 10 No. 2 (2026): March 2026 Issue
Section
Poster Presentations at 2026 Winter Clinical Miami Dermatology Conference®
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 > >>